Co-Founding VoyagerMed: Selling Tech to Non-Tech Industries

Why Healthcare Was the Hardest — and Most Valuable — Sales Education of My Career

When I co-founded VoyagerMed in 2012, I walked in with a background spanning Wall Street, law, and enterprise software. I thought I understood how to sell complex solutions to sophisticated buyers. Healthcare humbled me quickly — and in doing so, gave me a framework for selling innovation into risk-averse industries that I've relied on for every company I've built since.

VoyagerMed was a technology-enabled healthcare access platform designed to improve how patients connected with specialists and how institutions managed referral workflows. The value proposition was clear, the technology was solid, and the market need was real. None of that mattered as much as I expected. Because in healthcare circa 2012, being a tech startup wasn't a credential — it was a liability.

The Trust Barrier Is Not a Sales Problem — It's a Structural One

Healthcare buyers — physicians, hospital administrators, health systems, payers — operate inside a culture shaped by liability, patient safety, regulatory compliance, and decades of vendor relationships built on personal trust. When you approach that world as a startup with a new platform, you're not just asking them to buy software. You're asking them to take on risk. Professional risk. Institutional risk. In some cases, patient safety risk.

Standard SaaS sales tactics don't penetrate that. Discovery calls, demo-to-close cycles, ROI calculators — these tools assume the buyer is evaluating your product on merit within a framework they already trust. In healthcare, the framework itself has to be built first. You don't start with the product. You start with the relationship, the credibility, and the proof that you understand their world well enough to be taken seriously.

We spent the first several months of VoyagerMed not selling — we were listening, learning, and showing up consistently enough that physicians and administrators started to see us as domain peers rather than outside vendors.

That distinction matters enormously. A vendor pitches. A peer solves problems. We had to become the latter before we could become the former.

What "Earned Credibility" Actually Looks Like in Practice

Earning credibility in a non-tech industry isn't about having the right certifications or putting the right logos on a slide deck. It's behavioral. It's about demonstrating, through every interaction, that you understand the constraints, language, incentives, and risk tolerance of the buyer's world — and that you're not going to create new problems while solving the one you're pitching.

At VoyagerMed, this meant several concrete things:

• Speaking the clinical language, not the tech language. We talked about workflow impact, patient outcomes, and referral velocity — not API integrations, uptime SLAs, or feature roadmaps. The technology was the means, not the message.
• Leading with outcomes from early adopters, not projections. Healthcare buyers don't trust forecasts. They trust case studies. Getting the first two or three physician groups live and generating real data was worth more than any pitch deck we ever built.
• Building institutional relationships before transactional ones. Hospital systems and medical groups are hierarchical. Working through the right channels — medical directors, department heads, credentialed clinical staff — rather than circumventing them was non-negotiable.
• Being visible in their professional environment. Conferences, CME events, clinical roundtables. Not as a vendor sponsor, but as a participant. When a physician saw us consistently engaging with their professional community, we stopped being an outsider.

The Compounding Skepticism Problem

One dynamic I hadn't fully anticipated was how skepticism compounds in tight professional networks. Healthcare is a highly referential industry. Physicians talk to other physicians. Hospital administrators compare notes at industry conferences. If you push too hard, overpromise, or misrepresent your capabilities — even once — that information travels faster than any sales motion you could run. The downside risk of aggressive selling in that environment is permanent reputational damage in the very network you need to penetrate.

This forced a discipline in our go-to-market that I've carried forward: the speed of trust-based selling is slower in the short run and dramatically faster in the long run. Every physician or administrator who became a genuine advocate did more pipeline generation through word-of-mouth than a dedicated SDR running outbound sequences ever could.

What Transferred — and What I Apply Today

The skills I built at VoyagerMed didn't stay in healthcare. They became a core part of how I approach sales leadership and GTM strategy in every domain I've worked in since.

At Scoro, we were selling work management software into professional services firms — accountants, consultants, agencies — that had entrenched workflows and strong preferences for tools their teams had used for years. The same principle applied: lead with their language, build credibility through early outcomes, and never let the technology outrun the relationship.

At Decile, selling data analytics and customer intelligence into retail and DTC brands, we were often educating buyers on a category they hadn't fully internalized yet. Again, the trust-first motion was more effective than product-led growth alone. The buyers who converted through genuine understanding of the value had dramatically better retention and expansion trajectories than those who came in through volume-driven acquisition.

Now, at HedgeNova, I'm building an AI-powered platform for hedge fund intelligence in an industry — institutional finance — that is arguably even more skeptical of external technology than healthcare was in 2012. The instinct of every senior PM or CIO at a hedge fund is to protect proprietary edge, not to expose workflows to a third-party AI system. The trust barrier is structural, cultural, and deeply rational. VoyagerMed taught me not to fight that instinct — but to understand it, respect it, and build the kind of credibility that eventually makes it a non-issue.

The Underlying Principle: Selling Innovation Into Risk-Averse Industries

There's a version of startup culture that treats institutional skepticism as an obstacle to be overcome — something to bulldoze through with enough volume, velocity, or venture capital. That approach fails consistently in any industry where the buyer's professional reputation is on the line.

The better frame is this: risk-averse buyers aren't irrational — they're rational under a different set of constraints than you're used to working with. Your job as a founder or sales leader is to map those constraints precisely, then build a go-to-market that reduces the perceived risk of adopting your solution to a level where the buyer's internal ROI calculus finally tips in your favor.

That takes longer. It requires genuine domain depth, not just sales skill. It demands patience from investors and boards who want to see shorter sales cycles. But when it works, the customer relationships you build are durable, expansive, and defensible in ways that growth-hacked customer bases simply are not.

VoyagerMed taught me that. It's still one of the most valuable things I've built in thirty years of building companies.